| Clinical data | |
|---|---|
| Trade names | Fexuclue |
| Other names | Abeprazan; DWP14012; DWP-14012 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H17F3N2O3S |
| Molar mass | 410.41 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fexuprazan (trade name Fexuclue) is a drug for the treatment of gastroesophageal reflux disease (GERD). It is a potassium-competitive acid blocker, which is a class of drugs suppressing gastric acids.
Fexuprazan is approved for clinical use in South Korea, Mexico, Philippines, Chile, and Ecuador.